Work

Rapid resistance profiling of SARS-CoV-2 protease inhibitors

Year: 2023

Type: article

Abstract: Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a robust cell-based assay is used to determine the relative potencies of nirmatrelvir, ensitrelvir, and FB2001 against a panel of SARS-CoV-2 main protease (M pro ) variants. The results reveal that these three drugs have at least partly distinct resistance mutation profiles and raise the possibility that the latter compounds may be effective in some instances of Paxlovid resistance and vice versa .

Source: npj Antimicrobials and Resistance

DOI: 10.1038/s44259-023-00009-0

Authors: Seyed Arad Moghadasi, Rayhan G. Biswas, Daniel A. Harki, Reuben S. Harris

Institutions: University of Minnesota, Howard Hughes Medical Institute, The University of Texas at San Antonio Health Science Center

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,190